4DMT lands up to $200M credit facility from Hercules Capital
What's the deal? 4D Molecular Therapeutics (Nasdaq: FDMT) has secured a strategic credit facility of up to $200 million from Hercules CapitalDealroom has a profile for this one. Try Dealroom →.
The Emeryville-based biotech, known as 4DMT, announced the agreement on June 29, 2026. Hercules Capital (NYSE: HTGC) is a specialty financier focused on life sciences and technology companies.
Why now? The deal is structured as post-IPO debt, giving 4DMT non-dilutive capital to fund operations without issuing new shares.
As a late-stage biotech, the company is advancing disease-targeted therapeutics through costly clinical trials. The facility provides runway as it pushes treatments toward approval.
What could go wrong? Debt carries repayment obligations and interest, unlike equity. If trials stall or revenue lags, those commitments could strain the balance sheet.
Credit facilities also often include milestones and covenants. Drawing the full $200 million may depend on hitting clinical or commercial targets.
The signal: 4DMT's focus on gene therapy puts it at the capital-intensive frontier of biotech, where lengthy trials and high development costs make non-dilutive funding especially valuable. By tapping Hercules Capital's investment fund rather than issuing new equity, the late-stage company secures runway while protecting existing shareholders — a structure that has become a go-to for clinical-stage firms navigating a tight funding market.
Read more: aktiencheck.de
Image credit: Generated with Gemini
